Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study-Reference-Cited by-同舟云学术

Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study

Published:2023-05-20 Issue:8 Volume:28 Page:1073-1081
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Komori Azusa,Otsu Satoshi,Shimokawa Mototsugu,Otsuka Taiga,Koga Futa,Ueda Yujiro,Nakazawa Junichi,Arima Shiho,Fukahori Masaru,Okabe Yoshinobu,Makiyama Akitaka,Taguchi Hiroki,Honda Takuya,Shibuki Taro,Nio Kenta,Ide Yasushi,Ureshino Norio,Mizuta Toshihiko,Shirakawa Tsuyoshi^ORCID,Mitsugi Kenji

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02354-6.pdf

Reference31 articles.

1. Carrato A, Falcone A, Ducreux M et al (2015) A systematic review of the burden of pancreatic cancer in europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer 46:201–211

2. Egawa S, Toma H, Ohigashi H et al (2012) Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas 41:985–992

3. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

4. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

5. Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial;Cancer Immunology, Immunotherapy;2024-08-06